FDA Inspection 1147067 — Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation — FEI 2210396

The FDA completed an inspection of Novartis Pharmaceuticals Corporation on July 9, 2021 in East Hanover, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
July 9, 2021
Fiscal Year
2021
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
East Hanover, NJ (United States)

Additional Details

Sponsor, Contract Research Organization